P300 latency changes in patients with mild cognitive impairment after taking choline alphoscerate; A preliminary study

Choline alphoscerate in clinical studies improved cognitive dysfunction in dementia, but it did not show any clear clinical benefit on mild cognitive impairment (MCI). There is limited evidence of neuropsychological markers in showing the effects of cholinergic precursors in MCI. Object of this prel...

Descripción completa

Detalles Bibliográficos
Autores principales: Han, Su-Hyun, Jeong, Hae-Bong, Park, Kwang-Yeol, Shin, Hae-Won, Youn, Young Chul, Kim, SangYun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007142/
https://www.ncbi.nlm.nih.gov/pubmed/29928709
http://dx.doi.org/10.1016/j.ensci.2018.04.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6007142/
https://www.ncbi.nlm.nih.gov/pubmed/29928709
http://dx.doi.org/10.1016/j.ensci.2018.04.004

Ejemplares similares